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AbstrAct
Background Diabetes peer support, where one person 
with diabetes helps others, may improve diabetes 
management. The objective of this study was to 
perform a cost analysis of peer support strategies used 
in RAndomized controlled trial of Peer Support in type 
2 Diabetes.
Methods We performed a 2×2 factorial randomized 
cluster controlled trial in England. People with type 2 
diabetes were invited to participate as either ‘peer’ or 
‘peer support facilitator’ (PSF) through postal invitation 
predominantly from general practice. Clusters, based 
on local communities, were each randomly assigned 
to one arm of group, 1:1, both group and 1:1 or control 
interventions. The intervention was delivered over 
8–12 months by trained PSFs, supported by monthly 
meetings with a diabetes nurse. Out-of-pocket 
expenses/service utilization were self-reported at 
baseline, midpoint and on trial completion. Intervention 
costs were collated. Non-hospital costs used National 
Health Service (NHS) reference costs. Hospital 
payments were obtained from one local commissioning 
group and mean payments calculated. The analysis 
employed a societal perspective. Costs were evaluated 
at the conclusion of the trial.
Results Participants (n=1299) were recruited across 
130 clusters. The four arms were well balanced and 
matched (60% male, mean diabetes duration 9.5 years, 
mean glycated haemoglobin (HbA1c) 7.4+/-1.3%, 17% 
insulin treated). Implementation costs at 2013 rates 
were £13.84/participant/annum, participant out-of-
pocket expenses for any intervention were £11.41/
participant/annum and the NHS-incurred costs were 
reduced by £138.38/participant/annum. Savings for the 
1:1, group and any intervention were £233.65, £90.52 
and £113.13/participant/annum, respectively.
Conclusions We conclude that both 1:1 and group 
diabetes peer support over 8–12 months are cost 
saving in this setting, although much of the benefit 
is largely derived by differences in self-reported 
healthcare utilization. Long-term benefits should be 
investigated.
Trial registration number ISRCTN66963621
InTRoduCTIon
Diabetes imposes a substantial economic 
burden in the UK with estimated costs that 
account for nearly 10% of the National 
Health Service (NHS) resource expenditure.1 
In order to achieve sufficient control of their 
disease, people with diabetes must engage in 
a number of self-care activities such as plan-
ning meals, exercising on a regular basis, 
monitoring of blood glucose levels/taking 
medication for some, and checking their 
feet on a routine basis.2 3 While these behav-
ioral and lifestyle changes are indispensable 
for proper diabetes management, they pose 
significant lifestyle and behavioral changes 
for people with diabetes and can be difficult 
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significance of this study
What is already known about this subject?
 ► The clinical impact of peer support in type 2 
diabetes varies in different populations. Few health 
economic analyses of diabetes peer support have 
been undertaken and those that have been are 
contradictory.
What are the new findings?
 ► Based on data from RAndomized controlled trial 
of Peer Support in type 2 Diabetes, the largest 
randomized controlled trial of diabetes peer support 
undertaken, diabetes peer support, whether 
delivered through 1:1 and/or group interactions, was 
cost effective.
How might these results change the focus of 
research or clinical practice?
 ► Health services should consider embedding diabetes 
peer support into their care pathways. Long-term 
studies of the effects of diabetes peer support are 
needed to assess the sustainability of these results.
group.bmj.com on September 14, 2017 - Published by http://drc.bmj.com/Downloaded from 
2 BMJ Open Diab Res Care 2017;5:e000328. doi:10.1136/bmjdrc-2016-000328
Epidemiology/Health Services Research
to implement. Accordingly, a multifaceted approach is 
essential in empowering patients to manage the self-care 
activities associated with proper diabetes management.2
One strategy that has been endorsed by the WHO to 
assist people with diabetes with managing their diabetes 
is peer support.4 Peer supporters also have diabetes, 
and lend assistance to other patients in several areas 
such as providing social and emotional support, linking 
peers to clinical care, and providing encouragement in 
managing the day-to-day activities of living with diabetes.5 
Peer support can take on either individual or group 
approaches and can involve in person, telephone or 
internet modalities of communication.6–8
Several randomized controlled trials (RCTs) have been 
conducted in order to evaluate the impact of peer support 
on clinical outcomes7 8; however, there have been less data 
on the economic outcomes of peer support in diabetes 
as a recent review noted that more research needs to be 
done in this area.9 One study that assessed the cost-ef-
fectiveness of group-based peer support compared with 
standard of care in a cluster randomized trial was among 
patients with diabetes in Ireland. Using both in trial and 
beyond trial data, the investigators demonstrated that 
group-based peer support was associated with a gain of 
0.09 quality-adjusted life years (QALYs) over the course 
of a patient’s life with a corresponding decrease in cost of 
over €637.10 A separate analysis regarding the cost-effec-
tiveness of group-based peer support in a RCT setting was 
conducted for patients with impaired fasting glucose or 
newly diagnosed type 2 diabetes in the UK. Group-based 
peer support was associated with nearly £226 in incre-
mental cost and a mean QALY gain of 0.003 so that over 
£67 000 was spent for each additional QALY gained.11 A 
different type of cost-effectiveness evaluation evaluating 
peer support in diabetes was conducted among Hispanic 
populations in the USA. In this evaluation, peers were 
in the form of community health workers (CHW) and 
group-based classes were delivered at medical facilities 
by the CHW. However, the CHW also visited the homes 
of patients where they had one-on-one interaction. This 
programme was determined to be cost-effective with a 
cost of just over $33 300 per QALY gained when compared 
with usual care.12
Additional studies have been conducted regarding the 
economic outcomes of peer support in diabetes without 
adopting a cost-effectiveness approach but rather a cost 
analysis. A secondary analysis of a controlled trial demon-
strated that group-based peer support was able to reduce 
the number of days spent in the hospital for patients with 
diabetes in the city of Salzburg, Austria when compared 
with control group patients. Although no significant 
impact was seen in prescription drug use, the annual 
savings associated with the group-based peer support 
amounted to over €1660 per patient.13 A randomized 
trial conducted in the USA indicated that group-based 
peer support was associated with a significant decrease 
in emergency room utilization and specialty visits when 
compared with usual care. However, there was also a 
significant increase in primary care visits and no change 
in the proportion of people admitted to the hospital so 
that there was no change in total costs.14 In contrast, a 
retrospective study conducted in the USA found that 
education sessions with peers had no significant impact 
on total costs or use of emergency department visits 
or inpatient hospital stays.15 Research has also been 
conducted that examines the implementation cost of 
peer support programme without providing data on the 
resulting impact on healthcare utilization or total health-
care costs.16
Although previous studies have examined the 
economic value of various forms of peer support, there 
is a scarcity of literature providing an economic evalua-
tion of the comparative benefits of both individual and 
group-based peer support. In this study, we present an 
economic evaluation of the RAndomized controlled 
trial of Peer Support in type 2 Diabetes (RAPSID). The 
RAPSID trial was designed to compare the efficacy of 
individual or group peer support,17 18 and the economic 
evaluation provides decision makers with data regarding 
the impact on health-related costs when implementing 
either or both forms of peer support.
MeTHods
overview
An economic evaluation was performed to evaluate the 
impact of peer support on costs in the RAPSID trial, a 
cluster RCT with a 2×2 factorial design (Trial registration 
number: ISRCTN66963621). Peer support was deliv-
ered via 1:1, group, or both group and 1:1 peer support 
(combined) and compared with a control group receiving 
standard diabetes care. Participants were recruited 
primarily by written invitation from their general prac-
tice, augmented by posters in the community and 1299 
patients were randomized to 130 clusters with up to 15 
participants in each cluster. Approximately 60% of the 
participants were male and they had been diagnosed 
with diabetes an average of 9.5 years earlier. The mean 
HbA1c of participants at baseline was 7.4% (SD=1.3%) 
and nearly 17% reported taking insulin at baseline.17 18
The intervention had two distinct phases. The first 
phase was delivered within the first 6 months and focused 
on three essential elements of diabetes management, 
namely overcoming practical obstacles encountered 
while dealing with diabetes, coping with the social and 
emotional aspects of diabetes and the type of medical 
therapy used in caring for diabetes. Just over 60% (61.4%) 
were able to attend a session where they had face-to-face 
contact with a peer support facilitator (PSF),17 18 but 
most participants (92.6%) were at least in contact by tele-
phone.
At trial conclusion, allocation to peer support was asso-
ciated with a decrease of 2.3 mm Hg (95% CI 0.6 to 4.0, 
p=0.008) in systolic blood pressure. No statistically signifi-
cant effect was demonstrated on HbA1c or other relevant 
psychosocial or behavioral variables measured during 
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Table 1 Unit costs used to estimate cost incurred during 
the RAPSID trial
Type of cost
Value 
(2013 £) Reference
Accident and emergency room visit 941.53 *
Overnight hospital stay 2696.24 *
Practice nurse 13.43 13
General practitioner 66 13
Diabetes specialist nurse 19.5 13
Healthcare assistant 8.4 13
Dietician 11.9 13
Consultant 39.9 13
*Emergency department and inpatient stay costs were 
obtained from the Cambridgeshire and Peterborough Clinical 
Commissioning Group for 90% of patients within their catchment 
area.
RAPSID, RAndomized controlled trial of Peer Support in type 2 
Diabetes.
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the trial.17 18 A cost analysis was deemed appropriate as 
opposed to a cost-effectiveness analysis as no statistically 
significant difference was demonstrated on HbA1c or 
quality of life in the clinical trial.
Costs overview
All costs were expressed in 2013 pounds (£) and the UK 
retail price index was used to inflate costs from previous 
years to the base year values.19 20 Three broad categories 
of costs were included: the implementation costs of the 
intervention, costs incurred by the patient, and costs 
incurred by the NHS. The analysis employed a societal 
perspective, including the perspective of the patient’s 
and the NHS. Costs were analyzed over a 1-year period 
in accordance with the intervention being delivered over 
a period of up to 1 year. Discounting was not used as the 
study period did not exceed 1 year.
Intervention implementation costs
The costs of the intervention included providing a phys-
ical facility for peer support meetings included those 
for the venue, refreshments, and mobile telephone top 
up vouchers for each cluster of patients. These costs 
amounted to £10.95 monthly for each cluster or £131.40 
pounds annually. The costs for the RAPSID nurse to 
participate in and travel to PSF meetings amounted 
to £36.2 pounds annually per cluster. The facilitator 
meeting costs included the costs for the nurse’s time and 
travel to the meetings. The costs required to train PSFs 
included costs for a booklet, venue, catering, and costs for 
the trainer. The training costs for PSFs costs was £39.98 
per cluster annually. In total, the annual cost required 
for implementing the intervention amounted to £207.58 
pounds per cluster. Because a cluster could have up to 15 
participants, the implementation cost of the intervention 
amounted to £13.84 per participant annually. Further 
detail on these costs is available elsewhere.18
Patient incurred costs
Patients provided self-reported information regarding 
their annual out-of-pocket expenditures for healthcare 
in surveys administered to them during the trial. Surveys 
were administered face to face at baseline, at 4–6 months 
via mail, and face to face at 8–12 months.18 This self-re-
ported data weres used to estimate the out-of-pocket costs 
incurred by patients in several areas over the previous 
12 months: medications, glucose monitoring, visits to 
healthcare professionals (practice nurse, general prac-
titioner, dietician, or podiatrists), travel to and from 
meetings, participation in weight loss groups, additional 
costs related to diabetes expenditures, and any other 
health services. Because it is rare for patients in the UK 
to pay for visits to health professionals and diabetes medi-
cations out of pocket, we performed an analysis where 
these costs were set to zero.
nHs incurred costs
Usual care in both intervention and control communities 
was based in primary care, with regular reviews conducted 
by general practitioners or practice nurses, either annu-
ally or more frequently if needed. Care was organized at 
a practice level, drawing on local guidelines, and incen-
tivized through the National Quality and Outcomes 
Framework. Patients were referred for specialist care at 
the discretion of the general practitioner. At the time they 
were surveyed, patients were also able to self-report the 
number of times they used various healthcare resources 
during the previous 6 months. These included accident 
and emergency visits, overnight hospital stays related to 
diabetes, and visits to various healthcare professionals 
(practice nurse, general practitioner, diabetes specialist 
nurse, healthcare assistant, dietician, or consultant). 
Following the example of a previous study, we multiplied 
the self-reported utilization by the unit cost to determine 
the total cost incurred during the year.21
The NHS incurred unit costs for each visit to a health 
professionals was derived from the Unit Costs of Health 
and Social Care data (table 1).22 Actual NHS hospital 
emergency department and inpatient stay costs were 
obtained from the Cambridgeshire and Peterborough 
Clinical Commissioning Group (which ‘pays’ for the 
hospital costs) which included 90% of study patients. The 
mean cost of the accident and emergency department 
visit and inpatient stay were calculated from this database 
and used as the mean cost of an accident and emergency 
department visit and inpatient stay in this study (table 1).
Analysis
All analyses were conducted in SPSS V.22. During the 
analysis, the 2×2 factorial design was taken into account so 
that the analyses evaluated the main effects of one-to-one 
peer support and group peer support on costs. As in 
another economic evaluation in diabetes, multiple impu-
tation was used in order to impute missing cost values 
conditional on gender, age, duration of diabetes, and the 
patient’s self-reported baseline HbA1c level.21 For each 
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Table 2 Costs during RAPSID at baseline and study end*
Baseline Study end
Control 1:1 Group Combined Control 1:1 Group Combined
Out-of-pocket costs for participants Mean Value Mean Value
  Medications 8.99 7.53 6.65 12.47 4.37 4.78 5.62 5.97
  Glucose monitoring 2.21 3.12 6.47 3.81 6.27 9.12 13.64 11.22
  Costs for medical visits† 74.57 86.13 151.15 112.71 49.69 51.65 86.40 64.40
  Travel to appointments 16.95 15.25 23.06 17.69 36.10 39.70 43.49 48.65
  Additional expenses‡ 136.99 131.51 176.26 148.26 181.91 182.24 207.66 208.83
  Total excluding covered services§, 156.15 149.87 205.79 169.76 224.29 231.06 264.79 268.71
  Total including all costs¶ 239.70 243.52 363.59 294.94 278.34 287.49 356.80 339.08
NHS incurred costs
  Accident and emergency visits 274.63 321.32 329.84 303.17 389.66 365.66 408.04 471.12
  Overnight hospital stay 329.73 516.66 341.82 962.86 796.63 948.68 902.03 991.14
  Nurse and General Practitioner 
costs 166.60 160.86 166.82 156.99 100.18 93.78 101.77 100.45
  Other health professionals 52.94 56.50 65.13 59.63 41.54 45.51 53.02 52.47
  Total NHS incurred costs 823.90 1055.34 903.62 1482.66 1328.01 1453.63 1464.86 1615.19
*All costs reported in 2013 £.
ϮIncludes visits to general practitioner, practice nurse, dietician, and podiatrists.
‡Includes travel to appointments, expenses for weight loss group, additional healthcare-related costs for diabetes expenses, and costs for 
other health services.
§Excludes medication costs and payments for medical visits traditionally covered by the NHS.
¶Includes sum of all reported out of pocket costs.
NHS, National Health Service; RAPSID, RAndomized controlled trial of Peer Support in type 2 Diabetes.
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type of cost incurred by participants or the NHS during 
the trial, we determined the change in costs from baseline 
to the conclusion of the trial. The mean change in costs 
after adjusting for baseline values was compared across 
the groups that patients were randomly assigned to for 
out-of-pocket costs, NHS incurred costs and total costs 
(combined out-of-pocket and NHS incurred costs). For 
the patients assigned to peer support, we also added the 
implementation costs of the peer support intervention. 
Ethics approval was received from the Cambridgeshire 
REC2 Committee (10/H0308/72), and signed consent 
included agreement for access to hospital data.
ResulTs
Table 2 shows the out-of-pocket expenses as reported by 
participants in the questionnaire. The data set included 
some participants who had reported drug and GP/prac-
tice nurse visit costs. However, in the UK, these costs 
are covered by the taxpayer and are free to the user 
(with rare exceptions). At baseline, when assuming that 
patients incurred no costs for medications or medical 
visits, the mean reported out-of-pocket costs ranged from 
£149.87 to £205.79 depending on the group the patient 
was assigned to. At the conclusion of the trial, the mean 
reported out-of-pocket costs for the groups ranged from 
£224.29 to £268.71 pounds when excluding the costs for 
medications and medical visits. When including all costs, 
the mean total out-of-pocket costs varied from £239.70 to 
£363.59 depending on the group patients were random-
ized to. At the end of the study, the average reported out 
of pocket costs varied from £278.34 to £356.80 pounds 
depending on the group the patient was assigned to.
Table 2 also presents the NHS incurred costs at base-
line and study end. During the baseline study period, the 
mean estimated NHS incurred costs for the groups were 
between £823.90 to £1482.66. At the conclusion of the 
study, the average estimated NHS incurred costs for the 
groups varied from £1328.01 to £1615.19.
Table 3 depicts the impact of the intervention on the 
patient’s out-of-pocket costs and the NHS incurred costs. 
Overall, the interventions had relatively little impact on 
the patient’s out-of-pocket costs, ranging from approxi-
mately £23 pounds saved per patient to an additional 
£28.40 per patient on an annual basis depending on 
the intervention and whether or not medications were 
included. However, when looking at NHS incurred costs, 
the intervention saved money in all situations, with the 
total savings ranging from £101.44 with the group inter-
vention to £267.00 with the one-on-one intervention. 
These savings were largely due to savings in overnight 
hospital stays where the intervention was associated 
with mean savings between £124.64 to £283.04 pounds 
depending on which intervention patients received.
Table 4 demonstrates that the peer support interven-
tion was cost saving when looking at the combined patient 
and NHS perspective. The savings ranged from £90.52 
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Table 3 Intervention impact on costs incurred in RAPSID*
Study group
One to one Group Any intervention
Out-of-pocket costs Mean, 95% CI
  Change in medications −1.81 (−7.02 to 3.41) −0.06 (−5.25 to 5.13) 1.21 (−4.72 to 3.03)
  Change in glucose monitoring 1.06 (−3.12 to 5.25) 2.26 (−1.80 to 6.31) 2.80 (−1.81 to 7.41)
  Change in costs for medical 
visits†
7.90 (−3.39 to 19.19) 3.81 (−5.76 to 13.38) 6.09 (−6.20 to 18.37)
  Change in travel costs 3.69 (−28.91 to 36.30) −26.92 (−67.03 to 13.18) −24.39 (−63.62 to 14.86)
  Change in additional out-of-
pocket expenses‡
17.55 (−31.78 to 66.88) −2.03 (−53.14 to 49.07) 2.52 (−48.73 to 53.77)
  Intervention impact on 
total out-of-pocket costs 
(medications and patient visits 
included)§
28.40 (−39.81 to 96.61) −22.95 (−96.45 to 50.56) −11.76 (−85.84 to 62.31)
  Intervention impact on total 
out-of-pocket costs (No 
medications or patient visits)¶
26.51 (−19.40 to 72.42) 4.04 (−47.99 to 56.06) 11.41 (−37.94 to 60.76)
NHS incurred costs
  Accident and emergency visits 9.46 (−109.50 to 128.43) 43.00 (−77.50 to 163.50) −18.52 (−161.39 to 124.34)
  Overnight hospital stay −283.04 (−726.36 to 160.29) −151.87 (−625.06 to 321.31) −124.64 (−639.92 to 390.64)
  Nurse and General Practitioner 
costs
3.89 (−22.31 to 30.11) 5.91 (−19.83 to 31.64) 3.50 (−27.54 to 34.55)
  Other health professionals 2.68 (−6.93 to 12.29) 1.53 (−7.74 to 10.78) 1.29 (−9.43 to 12.01)
  Intervention impact on NHS 
incurred costs during trial
−267.00 (−758.02 to 224.01) −101.44 (−600.75 to 397.86) −138.38 (−706.68 to 429.92)
*All costs reported in 2013 £.
ϮIncludes visits to general practitioner, practice nurse, dietician, and podiatrists.
‡Includes travel to appointments, expenses for weight loss group, additional healthcare-related costs for diabetes expenses, and costs for 
other health services.
§Includes sum of all reported costs.
¶Excludes medication costs and payments for medical visits traditionally covered by the NHS.
NHS, National Health Service; RAPSID,RAndomized controlled trial of Peer Support in type 2 Diabetes.
Table 4 Net costs or savings for interventions during the RAPSID trial*
Study group
One to one Group Any intervention
Mean (95% CI)
Impact on participants out-of-
pocket costs
26.51 (−19.40 to 72.42) 4.04 (−47.99 to 56.06) 11.41 (−37.94 to 60.76)
Impact on NHS incurred costs −267.00 (−758.02 to 224.01) −101.44 (−600.75 to 397.86) −138.38 (−706.68 to 429.92)
Net cost or savings incurred with 
implementation cost of 13.84£ for 
those receiving peer support
Savings of £233.65 
(−734.06 to 267.52)
Savings of £90.52
(−598.87 to 417.83)
Savings of £113.13
(−616.82 to 390.55)
*All costs reported in 2013 £.
NHS, National Health Service.
Epidemiology/Health Services Research
with group peer support to £233.65 with one-to-one peer 
support. Although there were additional costs due to 
implementation of the intervention and modest addi-
tional out-of-pocket costs imposed on the patient, these 
were more than offset by the NHS incurred savings.
dIsCussIon
We found that peer support, in either a group format or 
one-to one delivery, is associated with lower overall total 
healthcare costs during the time period the intervention 
is being delivered. The cost savings are largely due to 
decreased hospitalization expenses which are incurred 
by the NHS, but the intervention is associated with a 
modest increase in out-of-pocket costs for participants 
and implementation costs. The increase in out-of-pocket 
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costs associated with the intervention may be at least 
partially due to patients engaging in self-care activi-
ties. For example, intervention patients tended to have 
a greater increase in glucose monitoring over the trial 
period when compared with control patients. If inter-
vention patients were able to engage in more intensive 
self-management of their diabetes, then this should lead 
to fewer complications and hospitalizations with their 
diabetes.
The results from this study are in agreement with those 
from a previously reported cost analysis of peer support 
in diabetes indicating that group-based peer support was 
associated with a decrease in inpatient hospital utilization 
and total healthcare costs among patients in Austria.13 
However, a randomized study conducted within the USA 
found no differences in total cost or hospital utilization 
when conducting a cost analysis.14 This may be due to the 
fact that the study was conducted in a different health-
care system in the USA and the fact that median value was 
used to quantify differences in healthcare costs. Another 
retrospective study conducted in the USA also failed to 
demonstrate an appreciable difference in healthcare 
costs when comparing peer support to standard of care.15
One strength of this study is that it is an economic eval-
uation of the only RCT including one-to-one and group 
peer support.18 There is sparse data comparing group 
and one-to-one peer support in terms of their impact on 
costs in diabetes. However, the currently available data 
suggest that one-to-one interventions may be more costly 
to implement than comparable interventions delivered 
in a group setting.23 Yet, data from a recent review suggest 
that peer support delivered in a one-to-one format may 
be more effective for glycemic control than group-based 
peer support in many cases which may lead to lower utili-
zation of health services over time.8 More research needs 
to be done in this area to elucidate the comparative 
impact of group and one-to-one peer support on costs 
among people with diabetes.
Another strength, although potentially a weakness as 
well, is that our study was also able to incorporate esti-
mated costs from both the patient perspective as well as 
that of the NHS. In addition, we were able to obtain actual 
data in regards to hospitalization costs which provide a 
more accurate assessment of the costs than the unit costs 
data. However, we had to rely on patient’s self-reported 
responses to determine the utilization of healthcare 
services, and this had a substantial impact on our results. 
This may be subject to recall bias, although this method-
ology has been used in previous studies evaluating costs 
related to peer support in diabetes patients.11 In addi-
tion, patients reported out-of-pockets costs for services 
and items such as medications, glucose test strips and 
visits to the general practitioner that are typically paid 
for by the NHS. It should be noted, however, that recent 
reports indicate that the provision of test strips may be 
limited for certain patients or excluded all together due 
to supply issues or budgetary concerns.24–26 We accounted 
for this by including an analysis with these out-of-pocket 
costs included as well as an analysis where these costs 
were excluded. The use of self-reported data may also be 
responsible for some of the relatively large variation seen 
in some of the data.
A further weakness of the study is the short period of 
follow-up and the actual limitations of the hospital data. 
While we report that peer support is associated with a 
decrease in hospitalization costs during the short term 
for patients with diabetes, the specific types of hospital-
ization that were prevented are not fully understood as 
of yet. Future studies should address this issue. Moreover, 
we have explored the short-term impact of the RAPSID 
intervention on healthcare costs, but the impact on long-
term costs is uncertain. However, it is possible that the 
intervention could produce a favorable impact on long-
term healthcare costs due to the positive effect on blood 
pressure.27
In conclusion, we have shown that both 1:1 and group 
diabetes peer support are cost saving over 8–12 months 
in this setting. Long-term benefits should be investigated.
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